Research & Education

Radiation Webinar - Stereotactic Ablative Radiotherapy

Tuesday, July 21, 2015 - 1 p.m. CEST - Recording Available

The IASLC Education Committee is pleased to announce the continuation of a series of Live Webinars presented by the Advanced Radiation Technology Committee. This subcommittee is focused on providing educational and informational programs addressing state of the art radiation therapy for lung cancer. This live program will be moderated by Francoise Mornex, MD, PhD and feature presentations by Dr. David Palma and Professor Suresh Senan.

Françoise MORNEX David Palma Suresh Senan 

Program Chair
PR Françoise Mornex , MD, PhD

Département de Radiothérapie
Centre Hospitalier Lyon Sud
LYON, France

David Palma, MD, PhD, FRCPC

Radiation Oncologist, London
Health Sciences Centre, Canada
Clinical-Scientist, Ontario
Institute for Cancer Research

Suresh Senan, MD, PhD, FRCR

Department of Radiation Oncology
VU University Medical Center in
Amsterdam, The Netherlands

Name of Reviewer(s): 

              

Fred Hirsch, MD, PhD –Speakers Bureau/Advisory Board: Astrazeneca, Genentech, BMS, Lilly and Abbvie.

Name of Planner(s): 

 

     Deb Whippen-Nothing to Disclose

 

Name of Activity: 

 

Stereotactic Ablative Radiotherapy

Date of Activity:

 

07/21/2015

Faculty/Speaker(s):

Financial DISCLOSURES

 

PR Françoise Mornex , MD, PhD-Moderator-Consulting for: Lilly, Roche and Boehringrt-Ingelheim

David Palma, MD, PhD, FRCPC- Speaker-Has Nothing to Disclose

Suresh Senan, MD, PhD, FRCR-Speaker- Member of trial management committee for proclaim trial sponsored by Eli Lilly

Speakers honoraria from Varian Medical Systems

Research agreement with Varian Medical Systems

RESOLUTION of COI: Ensure the activity includes a balanced discussion of alternative therapies.

“All planning committee members’ and/or faculty’s identified conflicts of interest pertaining to this activity were resolved prior to the activity.”

 

Type of Activity: 

 Live Course

  Internet Live Course (Webinar)

 Internet Enduring Material

Are there Commercial Supporters for this activity?

        Yes     

If yes, please list: Supported by an unrestricted grant from Elekta

 

Follow-up of patients after stereotactic ablative radiotherapy (SABR) for early-stage NSCLC:
A Primer for the Multidisciplinary Team

The use of SABR for early-stage NSCLC has increased rapidly in the past decade. With a shift toward treatment of fitter patients in recent years, long-term follow-up after SABR is of increasing importance. This webinar will review the rationale for CT follow-up after SABR, expected disease outcomes and radiologic changes, detection of recurrence, and management of recurrences or second primary lung cancers.

After attending this session attendees will be able to:

  1. Discuss the objectives of CT imaging surveillance after SABR for early-stage NSCLC
  2. Anticipate expected clinical and radiologic outcomes after SABR
  3. Discuss the detection and management of recurrence or second primary lung cancers

DOWNLOAD RECORDING

CME Information:

Financial/Commercial Relationships DISCLOSURES

A Conflict of Interest (COI) is created and exists when individuals in a position to control the content of CME, or their spouses/partners, that have a relevant personal financial relationship within the past 12 months with a commercial interest that produces, markets, re-sells, or distributes health care goods or services consumed by, or used, on patients that benefits the individual in any financial amount and therefore, may bias their opinions and teachings. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or any other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research and clinical trials), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities for which remuneration is received or expected. 

 This IASLC CME educational activity was planned and developed to: uphold academic standards to ensure balance, independence, objectivity, and scientific rigor; adhere to requirements to protect health information under the Health Insurance Portability and Accountability Act of 1996 (HIPAA); and, include a mechanism to inform learners when unapproved or unlabeled uses of therapeutic products or agents are discussed or referenced.

IASLC CME assures that the planners/reviewers/authors/faculty/moderators/peer reviewers et. al. conflicts of interest  were identified, reviewed and resolved from all individuals involved in the development  or able to influence and control the content of this CME activity; IASLC CME assures that disclosure is given prior to an educational activity being delivered to learners.  Any individual who failed or refused to disclose relevant financial relationships was disqualified from this CME activity and removed from any of IASLC CME activity presentation.

All commercial relationships and conflicts of interest that are identified are thoroughly vetted by IASLC Ethics Committee, CME Subcommittee, and Independent reviewer. COI will be evaluated by the Board of Directors of the IASLC for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. IASLC CME is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial entity.

CREDIT STATEMENT

IASLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

IASLC CME designates this Internet Live Course activity for a maximum of 1 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

GOAL & PURPOSE

This webinar will review the rationale for CT follow-up after SABR, expected disease outcomes and radiologic changes, detection of recurrence, and management of recurrences or second primary lung cancers.

TARGET AUDIENCE

This CME live webinar series is designed to meet the educational needs of healthcare professionals who diagnose and treat patients with lung cancer, including medical oncologists, thoracic surgeons, pulmonologists, radiation oncologists, radiologists, pathologists and advanced practice nurses and physicians' assistants.

DISCLAMER

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Thank you for your participation.

IASLC Financial /Commercial Relationships and Conflicts of Interest Policy

IASLC Honoraria Policy

IASLC Commercial Support Agreement (LOA)

Participants who complete a pre-and post-test along with an evaluation will receive 1 AMA PRA Category 1 CreditTM for each completed webinar.  

If you are interested in obtaining the CME Credits for these sessions you must indicate this when you register for the program. CME Credit is only available for those that participate in the Live Session.

This live webinar series is designed to meet the educational needs of radiation oncologists, medical oncologists, thoracic surgeons, radiologists, pathologists, and advanced practice nurses, physician's assistants and other healthcare professionals who diagnose and treat patients with lung cancer.

Location Local time Time zone UTC offset
New York (U.S.A. - New York) Tuesday, July 21, 2015 at 7:00:00 AM EDT UTC-4 hours
Paris (France) Tuesday, July 21, 2015 at 1:00:00 PM CEST UTC+2 hours
Amsterdam (Netherlands) Tuesday, July 21, 2015 at 1:00:00 PM CEST UTC+2 hours
London (United Kingdom - England) Tuesday, July 21, 2015 at 12:00:00 Noon BST UTC+1 hour 
Rome (Italy) Tuesday, July 21, 2015 at 1:00:00 PM CEST UTC+2 hours
Moscow (Russia) Tuesday, July 21, 2015 at 2:00:00 PM MSK UTC+3 hours
Brussels (Belgium) Tuesday, July 21, 2015 at 1:00:00 PM CEST UTC+3 hours
Dublin (Ireland) Tuesday, July 21, 2015 at 12:00:00 Noon IST UTC+1 hour
Barcelona (Spain) Tuesday, July 21, 2015 at 1:00:00 PM CEST UTC+2 hours
Los Angeles (U.S.A.) Tuesday, July 21, 2015 at 4:00:00 AM PDT UTC-7 hours 
Corresponding UTC (GMT) Tuesday, July 21, 2015 at 11:00:00 AM    

How to use the Time Zone Converter

This series is partially supported by an unrestricted grant from Elekta